Blood pressure medication recall over cancer risk expanded for more losartan drugs




  • In Business
  • 2019-01-24 02:25:38Z
  • By USA TODAY
 

As part of a growing number of blood pressure drug recalls, Torrent Pharmaceuticals has expanded its recall of losartan medication over concerns it contains a carcinogen.

Torrent said six additional lots of losartan potassium and hydrochlorothiazide tablets contain trace amounts of the probable human carcinogen N-nitrosodiethylamine (NDEA), according to a notice shared Tuesday by the Food and Drug Administration.

The India-based pharmaceutical company has already recalled 10 lots of losartan potassium tablets in the past two months, and since July, more than a dozen other recalls have been issued for common blood pressure medications.

The recalls have been linked to two overseas factories that made the drugs' active ingredients, which the FDA has said it is investigating. The drugs have been found to contain either NDEA or N-Nitrosodimethylamine (NDMA).

Check your medication: Here's how to see if your blood pressure meds are recalled over possible cancer risk

Various versions of valsartan, losartan and irbesartan drugs have been part of the recalls. These medications are part of a large class called angiotensin II receptor blockers (ARBs), which lower blood pressure by widening or relaxing blood vessels.

However, not all ARBs contain NDMA or NDEA or are under recall, and alternative treatments or medications can be prescribed in consultation with physicians, the FDA says.

The agency is telling patients to continue taking their medication "as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment," the FDA said.

Q&A: Why do blood pressure medications keep getting recalled? Here's what to know.

Click here to find out if your medication is affected by the recent recalls, or visit the FDA website. The agency has updated lists for all three kinds of drugs affected by the recalls.

Contributing: Ken Alltucker, USA TODAY. Follow USA TODAY's Ryan Miller on Twitter: @RyanW_Miller

Alternatives: Blood pressure drug substitutes are available for patients affected by recalls, doctors say

This article originally appeared on USA TODAY: Blood pressure medication recall over cancer risk expanded for more losartan drugs

COMMENTS

More Related News

Beyonce Had Pre-Eclampsia. Doctors Have New Ways to Detect and Treat It.
Beyonce Had Pre-Eclampsia. Doctors Have New Ways to Detect and Treat It.

VALERIE MACONBeyonce's revelation that she suffered from pre-eclampsia during her pregnancy highlights a dangerous condition that affects 5% of women and that scientists have recently developed new ways to detect and treat.In her new Netflix documentary, Homecoming, the superstar says she had an "extremely difficult pregnancy" due to high blood pressure before she gave birth to twins Sir and Rumi in 2017."My body went through more than I knew it could," she says.That's not an understatement. Preeclampsia can cause liver and kidney damage, seizures, stroke, and severe bleeding. It can trigger preterm labor and is the leading cause of premature births and maternal and fetal deaths in the...

Beyoncé Had Preeclampsia While Pregnant with Twins - How Serious (and Common) Is the Condition?
Beyoncé Had Preeclampsia While Pregnant with Twins - How Serious (and Common) Is the Condition?

Beyonce Had Preeclampsia While Pregnant - How Common Is It?

The FDA
The FDA's New Sugar Label Could Seriously Reduce Heart Disease and Diabetes-And Boost Longevity

A new study from Tufts University finds just how beneficial an added sugar label can be for our health and our wallets.

Amgen sets $21,900 annual price for new Evenity bone drug
Amgen sets $21,900 annual price for new Evenity bone drug

The U.S. Food and Drug Administration last week approved bone-building Evenity for postmenopausal women who are at high risk of fracture, but required the label to have a boxed warning, the FDA's strictest, flagging increased risk of heart attack, stroke and cardiovascular-related death. Since the drug's target population of older women has underlying risk for such cardiovascular problems, Wall Street analysts have pulled back on sales expectations for Evenity, which was developed jointly with Belgium-based UCB SA. Analysts, on average, project Amgen's Evenity revenue at $274 million a year by 2024, according to IBES data from Refinitiv. Sales of Amgen's older osteoporosis drug,...

Pre-Cut Melon Pulled From Kroger, Walmart and Other Groceries After It's Linked to Multi-State Salmonella Outbreak
Pre-Cut Melon Pulled From Kroger, Walmart and Other Groceries After It's Linked to Multi-State Salmonella Outbreak

Cut Melons at Kroger, Walmart, Target Linked to Salmonella Are Recalled

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business

facebook
Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.